Abingworth leads $22 mln Series A funding in SutroVax
Abingworth led a $22 million Series A funding in SutroVax, a biopharmaceutical vaccine company. Other participants in the funding include Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund.
24 July 2015•3 mins read
